Project 1: Nanodelivery of cannabinoids for treating epilepsy
Despite the impressive therapeutic advances of CBD in seizure disorders, one major drawback is its high first-pass metabolism and low oral bioavailability in humans. We aim to design a Nose-to-Brain Nano-Delivery system that will increase CBD brain exposure, reduce the number of drug administrations, increase protection from seizures, decrease side effects and thus improve the treatment of epilepsy and other CNS diseases.
Supervisors: Dr Tawfeeq Shekh-Ahmad (HUJI), Prof. Sara Eyal (HUJI), A/Prof. Nitin Mantri (RMIT), Prof. Leslie Yeo (RMIT) and Jonathan Grunfeld M.D. (MGC Pharma)
Project 2: Nanodelivery of cannabinoids for treating autism
This project will focus on targeting the cannabinoids system in autism as a therapeutic strategy. The overarching goal is to develop nano-pharmaceutical formulations for the optimal delivery of cannabinoids for treating autism spectrum disorder (ASD). In particular transmucosal and other delivery methods will be tested to identify the most optimal methods.
Supervisors: Dr Haitham Amal (HUJI), A/Prof. Nitin Mantri (RMIT), Prof. Leslie Yeo (RMIT) and Jonathan Grunfeld M.D. (MGC Pharma)
Project 3: Nanodelivery of cannabinoids for migraine
Migraine is a common neurological disorder, characterised by moderate to severe headache and nausea. While there is not currently a cure for migraine, there are treatments and lifestyle changes that can help patients manage their migraine and enjoy a normal life. Cannabinoids have been demonstrated to possess nausea and pain relief properties. This project aims to develop nanoformulation for delivery of cannabinoids to treat migraine.
Supervisors: Prof. Avi Priel (HUJI), A/Prof. Nitin Mantri (RMIT), Prof. Leslie Yeo (RMIT) and Jonathan Grunfeld M.D. (MGC Pharma)
